Introduction
Hematologic abnormalities are common complications of HIV infection and are estimated to affect from 11% to 75% of patients with HIV disease. [1] [2] [3] [4] Treatment with highly active antiretroviral therapy (HAART) generally improves hematologic abnormalities associated with advanced HIV disease in Western HIV-infected populations, 3 even though antiretroviral drugs such as zidovudine (ZDV) can cause anemia and leukopenia. 5 Hematologic abnormalities may be of greater concern in populations in sub-Saharan African, where comorbidities such as malnutrition, malaria, and parasitic infections are common, and capacity to monitor adverse events related to antiretroviral therapy (ART) is often limited. A combination of genetic and environmental factors may make hematologic abnormalities more common in African populations as compared to Western populations. 6, 7 Estimates of anemia in Africans range from 20% to 94%, with infants and pregnant women bearing the highest burden. [8] [9] [10] [11] Indeed, many ART programs in Africa have used stavudine (d4T) instead of ZDV as part of the first-line ART regimen, partly because of concerns about anemia in this population. Even in ART programs that do not use ZDV as part of the first-line ART regimen, a significant proportion of patients receiving d4T will need to be switched to ZDV because of toxicity. 12 Moh and colleagues 13 recently described unexpectedly high rates of severe neutropenia (neutrophil counts 750/mm 3 ) 6 months after initiating ZDV-containing ART in a cohort of patients already receiving cotrimoxazole in Cote d'Ivoire. However, HIV-infected patients who have already been treated with non-ZDV-containing ART for months or years before starting ZDV may subsequently have improved hematological profiles and better tolerate ZDV. We describe the hematologic changes associated with ZDV following single-drug substitution from d4T in a cohort of patients receiving HAART in a homebased AIDS care (HBAC) program in rural Uganda.
Methods
The HBAC program is a randomized ART-efficacy monitoring trial comparing 3 clinical monitoring strategies: arm A, clinical monitoring with quarterly CD4 counts and HIV viral loads; arm B, clinical monitoring with quarterly CD4 count measurements only; and arm C, clinical monitoring alone. HBAC is a collaborative project of The AIDS Support Organization ([TASO] a Ugandan HIV-care nongovernmental organization), the Ugandan Ministry of Health, and the US Centers for Disease Control and Prevention (CDC), to deliver and monitor ART and tuberculosis treatment at the homes of HIV-infected patients in Tororo and Busia Districts, Uganda. The program has been described elsewhere 14 but briefly, eligible patients who had a CD4 count 250 cells/mm 3 or WHO clinical stage 3 or 4 HIV disease and who lived within a 100-km 2 catchment area were provided ART, cotrimoxazole prophylaxis, treatment for tuberculosis as needed, adherence support, and HIV prevention education and services.
Participants in the current analysis were ART-naive adults enrolled in HBAC who started taking ART between May 1, 2003, and February 4, 2007 . We previously reported rates of clinical toxicity and single-drug substitutions for toxicity on a subset of this population. 12 In the present analysis, observation continued until death, loss to follow-up, or February 4, 2007, whichever occurred first. The first-line ART regimen was d4T, lamivudine (3TC), and nevirapine (NVP) or efavirenz (EFV). Didanosine (ddI), tenofovir (TDF), lopinavir/ritonavir (LPV/r), and ZDV were also available for second-line therapy. Patients who developed neuropathy requiring a drug change were usually changed from d4T to ZDV, unless their hemoglobin level was 8 g/dL, in which case they were changed to TDF.
Complete blood counts were measured quarterly on all patients enrolled in HBAC, so as to calculate absolute CD4 counts. These laboratory values were made available to physicians for patients in the arms randomized to receive CD4 monitoring (after February 2007, patients in arm C were rerandomized to arm A or arm B and had quarterly complete blood cell counts available in real time.). Hemoglobin tests could be ordered at any time for patients in any of the 3 arms. Neutrophil counts were not captured consistently so absolute neutrophil counts were not included in this analysis. Anemia was defined as a hemoglobin level 10 g/dL, leukopenia as a leukocyte count 2500/mm 3 , and thrombocytopenia as a platelet count 125 000/mm 3 . We graded abnormal values according to the 2004 US National Institutes of Health (NIH), Division of AIDS (DAIDS) criteria for grading the severity of adult and pediatric adverse events. 15 Hemoglobin levels were graded as follows: 8.5 to 10.0 g/dL (grade 1), 7.5 to 8.4 g/dL (grade 2), 6.5 to 7.4 g/dL (grade 3), and <6.5 g/dL (grade 4 We evaluated baseline rates of grades 1 to 4 (any) and grades 3 to 4 (severe) anemia, leukopenia, and thrombocytopenia for all patients before starting d4T (d4T baseline) and before starting ZDV (ZDV baseline) for the subset of patients who had single-drug substitution to ZDV. We performed Kaplan-Meier survival analyses to evaluate time to event of hematologic abnormality. We calculated the incidence of decline by at least one grade to any grade, or to any severe grade anemia, leukopenia, and thrombocytopenia for patients while they were receiving d4T and after they changed to ZDV. We did not perform direct statistical comparisons of hematological parameters between the time periods while patients were receiving d4T and while they were receiving ZDV, because all patients who received ZDV had also received d4T previously and because use of ZDV was conditional upon discontinuation of d4T. We performed univariate and multivariate Cox proportional hazards analyses to examine associations between incident abnormal hematologic values, and gender, body mass index (BMI; <18 vs !18 kg/m 2 ), age (!35 vs <35 years), CD4 count (<50 vs !50 cells/mm 3 ), tuberculosis treatment at baseline, anemia at baseline, and time on d4T before single-drug substitution to ZDV (!6 months vs < 6 months; !12 months vs <12 months). We used repeated measures analyses to estimate absolute means and to assess changes in hemoglobin levels, leukocyte counts, and platelet counts over time (from d4T or ZDV baseline, to 6 months, to 12 months, and to 24 months of d4T or ZDV therapy). All data were analyzed using SAS, version 9.1 (SAS Institute, Cary, NC).
Results
We The initial ART regimen was d4T and 3TC for all patients, with either NVP for 1049 patients (96.3%) or EFV for 40 patients (3.7%). The median observation time on d4T for all patients was 34.2 months. During the observation period, 309 patients (28%) changed from d4T to another drug; 294 (95%) because of neuropathy and 15 (5%) because of treatment failure. Of the 294 who changed drug because of neuropathy, 290 had a substitution to ZDV and 4 to TDF. All 15 who changed because of treatment failure changed to TDF. The median observation time on ZDV was 27.4 months per patient. Nineteen patients (6.6%) who received ZDV subsequently changed to TDF: 10 (3.4%) because of anemia and 9 (3.1%) because of a regimen change for treatment failure. Six of the patients who changed because of anemia required a blood transfusion for hemoglobin levels ranging from 2.5 to 5.1 g/dL; all of them recovered immediately after the transfusion. All patients requiring a blood transfusion had a single-drug substitution to TDF. The monitoring strategy arm to which the 10 persons with a single-drug substitution from ZDV to TDF due to anemia were assigned were arm A for 5, arm B for 4, and arm C for 1. Anemia was identified for those in arm A and arm B during routine reporting of the complete blood counts. Anemia was identified for 1 participant in arm C when a hemoglobin concentration of 7.0 g/dL was found during workup of an acute illness following 14 days of fever and a finding of pallor on examination, which was subsequently diagnosed as malaria. Although malaria may have been the cause of the anemia, the clinician made a single-drug substitution from ZDV to TDF. Blood drawn for a recent routine quarterly phlebotomy for this participant showed a hemoglobin concentration of 3.0 g/dL but that result was not available to the clinician due to blinding. There were an additional 4 participants in arm C who had a hemoglobin <8.0 g/dL while taking ZDV, but all 4 resolved within 3 months while continuing on ZDV.
Enrollment and follow-up characteristics of all 1089 patients who received d4T-containing ART, the 799 patients who did not have single-drug substitution to ZDV, and the 290 patients who had singledrug substitution to ZDV are presented in Table 1 . Patients with single-drug substitution to ZDV were older than those without ZDV substitution (Table 1) . At enrollment, 279 (25.6%) patients who initiated d4T-containing ART had anemia, 94 (8.6%) had leukopenia, and 147 (13.5%) had thrombocytopenia. At enrollment, 69 (23.8%) of the patients who later had ZDV substitution had anemia, 24 (8.3%) had leukopenia, and 39 (13.4%) had thrombocytopenia.
Overall, while taking d4T, 303 (27.8%) patients had a decline in hemoglobin level, leukocyte count, or platelet count by !1 grade from baseline (incidence rate [IR]: 0.83/100 PM), which in 47 (4.3%) cases was severe (IR, 0.12/100 PM; Table 2 ). While taking ZDV, 112 (38.6%) patients had a decline in hemoglobin level, leukocyte count, or platelet count by !1 grade from baseline (IR, 1.09/100 PM), which in 15 (5.2%) cases was severe (IR, 0.14/100 PM).
While taking d4T, 132 (12.1%) patients had a decline in hemoglobin levels by !1 grade from baseline (IR, 0.31/100 PM), which in 25 (2.3%) cases was severe (IR, 0.06/100 PM; Table 2 ). While taking ZDV, 32 (11.0%) patients had a decline in hemoglobin levels by !1 grade (IR, 0.44/100 PM), which in 8 (2.8%) cases was severe (IR, 0.11/100 PM). An increased hazard for anemia was associated with anemia at baseline (hazard ratio [HR], 2.72; 95% confidence interval [CI], 1.35-5.47) and with receiving !12 months of d4T before switch to ZDV (HR, 3.11; 95% CI, 1.34-7.19; Table 3 ). There was a statistically significant increase in hemoglobin levels from a mean of 11.3 g/dL at baseline to 12.2 g/dL at 6 months, to 12.8 g/dL at 12 months, and to 13.0 g/dL after receiving 24 months of d4T-containing ART (Figure 1 ). For patients with ZDV substitution, there was a significant decrease in mean hemoglobin levels from 12.6 g/dL at ZDV baseline to 12.3 g/dL at 6 months, followed by a nonsignificant increase to 12.4 g/dL at 12 months, and to 12.5 g/dL after receiving 24 months of ZDV (Figure 1 ). Despite the decrease in hemoglobin levels after change to ZDV, mean hemoglobin levels after 12 and 24 months on ZDV were higher than those before initiation of ART ( Figure 1 ). While taking d4T, 110 (10.1%) patients had a decline in leukocyte counts by !1 grade (IR, 0.29/ 100 PM), which in 8 (0.7%) cases was severe (IR, 0.03/100 PM). While taking ZDV, 76 (26.2%) patients had a decline in leukocyte counts by !1 grade (IR, 1.05/100 PM), which in 4 (1.4%) cases was severe (IR, 0.08/100 PM). An increased hazard for leukopenia was associated with receiving !6 months of d4T before switch to ZDV (HR, 2.58; 95% CI, 1.55-4.29; Table 3 ). There was a statistically significant increase in leukocyte counts while on d4T, from a mean of 4400/mm 3 at d4T baseline, to 5000/mm 3 at 6 months, followed by a nonsignificant decrease to 4900/mm 3 after 12 months, and to 5000/mm 3 after receiving 24 months of d4T-based ART (Figure 2 ). For patients with ZDV substitution, there was a significant decrease in mean leukocyte counts from 4700/mm 3 at ZDV baseline to 3900/mm 3 at 6 months, followed by a nonsignificant decrease to 3800/mm 3 at 12 months, and to 3900/mm 3 after receiving 24 months of ZDVcontaining ART (Figure 2 ). Mean leukocyte counts after 12 and 24 months on ZDV were lower than those before initiation of ART (Figure 2) .
While taking d4T, 121 (11.1%) patients had a decline in platelet counts by !1 grade (IR, 0.32/100 PM), which in 16 (1.5%) cases was severe (IR, 0.04/ 100 PM). While taking ZDV, 22 (7.6%) patients had a decline in platelet counts by !1 grade (IR, 0.30/ 100 PM), which in 3 (1.0%) cases was severe (IR, 0.04/100 PM). An increased hazard for thrombocytopenia was associated with having baseline thrombocytopenia (HR, 5.11; 95% CI, 2.11-12.37) and with receiving !12 months of d4T before switch to ZDV (HR, 5.90; 95% CI, 2.19-16.01; Table 3 ). There was a statistically significant increase in mean platelet counts while on d4T, from 219 000/mm 3 at d4T baseline to 247 000/mm 3 at 6 months, followed by a significant decrease to 239 000/mm 3 at 12 months, and to 240 000/mm 3 after 24 months of d4T-based ART. For patients with ZDV substitution, there were nonsignificant decreases in mean platelet counts from 254 000/mm 3 at ZDV baseline to 249 000/mm 3 at 6 months, 242 000/mm 3 at 12 months, and to 248 000/mm 3 at 24 months on ZDV (Figure 3 ). Mean platelet counts after 12 and 24 months on ZDV were higher than those before initiation of ART.
The incidence of hematologic abnormality did not differ significantly among patients in the different clinical monitoring strategies in the HBAC randomized trial (Table 3) . Additionally, multivariate analyses of factors associated with an increased hazard for anemia, leukopenia, or thrombocytopenia were all consistent with the univariate analyses presented.
Discussion
Hematologic parameters generally improved among patients taking d4T-containing ART and cotrimoxazole in this rural Ugandan population. A higher incidence of anemia and of leukopenia was observed after single-drug substitution from d4T to ZDV. However, median hemoglobin levels for patients who switched to ZDV remained higher than levels before starting HAART, suggesting that initial treatment with HAART improved hematologic abnormalities associated with advanced HIV disease, thus allowing patients to better tolerate ZDV. Overall, hematologic toxicity was not a major complication after singledrug substitution from d4T to ZDV in Uganda. Despite overall improvements in hematologic parameters after pretreatment with HAART, patients on ZDV are still at risk of developing anemia and need close monitoring; 10 (3.4%) of the 290 patients switched to ZDV needed a subsequent single-drug substitution because of anemia, and 6 (2.1%) had severe anemia necessitating a blood transfusion over a median observation period of 27.4 months. Programs will continue to have to weigh the benefits of using d4T which is commonly associated with nonlife-threatening but potentially debilitating toxicities like neuropathy, and uncommonly associated with life-threatening toxicities like lactic acidosis, versus those of ZDV which is more likely to cause life-threatening severe anemia. Still, these findings are reassuring for treatment programs that use ZDV for second-line treatment when substitution due to toxicity is necessary.
We observed that for patients changed to ZDV, median leukocyte counts declined after the substitution. A high incidence of leukopenia has been described in Africans receiving cotrimoxazole alone 16 and when cotreated with cotrimoxazole and ZDV. The phenomenon of benign ''ethnic'' neutropenia has been well described in African populations. [17] [18] [19] [20] Some authors have argued that the DAIDS criteria-which we used to define hematologic abnormality in this analysis-may not adequately describe hematologic profiles in healthy African populations, who usually have lower normal values than North American populations. [17] [18] [19] [20] The contribution of neutropenia to illness and death in this cohort is difficult to define, given our limited diagnostic capacity. A recent description of mortality among patients in HBAC determined that tuberculosis, cryptococcal disease, and candidiasis were the most common causes of death, but no specific clinical condition was identified in 41.5% of deaths. 21 We therefore cannot ascertain whether the mild leukopenia that we observed is clinically significant in this population. Mild leukopenia might be due to improper categorization of hematologic values, and a better description of normal hematologic parameters in African populations will be useful in guiding treatment, so that patients with normal values are not improperly categorized as having drug-related hematologic toxicity. We cannot exclude that the leukopenia we observed may also have resulted from an additive toxicity of coadministering cotrimoxazole with ZDV; a possibility that needs to be further explored, especially among Africans. Among patients receiving ZDV after a substitution from d4T, anemia, leukopenia, and thrombocytopenia present before starting any ART, were associated with Tolerance to Zidovudine in Uganda / Forna et al 135 development of the same hematologic abnormality while receiving ZDV-based HAART. Overall however, anemia present at baseline before starting ART improved while on d4T and after single-drug substitution to ZDV. Also reassuring was our observation that other baseline factors that might have made patients more prone to anemia including female gender and low CD4 count 1 were also not associated with development of anemia when switched to ZDV. The possibility that the period of treatment preceding switch to ZDV allowed patients at risk for anemia to better tolerate this antiretroviral drug when later substituted for d4T is a hypothesis that needs further investigation.
The overall impact of the routine reporting of complete blood counts along with CD4 counts was small, given the low frequency of single-drug substitutions triggered by the discovery of anemia. The frequency of single-drug substitutions from ZDV to TDF, due to anemia, was greater in arms A and B, in which complete blood counts were reported routinely, than in arm C in which these results were not available unless ordered. If clinicians had access to the routine complete blood cell counts in arm C, they probably would have switched 5 patients, given the hemoglobin results on quarterly testing. Interestingly, with the exception of the patient with pallor associated with hospitalization for malaria, the anemia resolved spontaneously by the next quarterly blood draw. These data denote that participants in arm C did not have as many single-drug substitutions from ZDV to TDF because the anemia found on routine phlebotomy in arms A and B was subclinical. Without routine reports of hemoglobin, if the anemia fails to lead to signs or symptoms, there is no impetus to change drugs. Patients in HBAC received cotrimoxazole prophylaxis and insecticide-treated bednets, which have been shown to decrease the incidence of malaria in this same population. 22 Decreased malaria burden may also have contributed to the low incidence of anemia after switch to ZDV; our findings might therefore not be generalizable to programs that do not offer these services. Our study design did not permit head-to-head comparison of patients while receiving d4T and after switch to ZDV, as participation in the ZDV group was conditional upon discontinuation of d4T. Finally, we were only able to present total leukocyte counts and therefore could not examine neutropenia directly.
In summary, in patients treated initially with d4T-containing ART for whom ZDV was later substituted due mostly to development of peripheral neuropathy, severe hematologic abnormalities typically associated with ZDV were uncommon and improvements in anemia during treatment with d4T were preserved. The decline in leukocyte counts after 12 months of treatment with ZDV combined with cotrimoxazole, which may have been clinically benign, warrants further investigation. Characterization of normal hematologic parameters in African populations is also warranted. Our findings suggest that in resource-limited settings ZDV may be safely substituted for d4T for treatment-limiting toxicity.
